13th Annual Updates in the Treatment and Management of Hematologic Malignancies Highlights from San Diego

The 13th Annual Updates in the Treatment and Management of Hematologic Malignancies Highlights from San Diego provides an invaluable educational experience highlighting the latest advances in malignant and non-malignant hematology. Please join us and engage with experts to learn and gain practical insights on current therapies, and innovative treatments. Available on-demand, this activity ensures that health care professionals caring for these patients have unlimited access to the latest scientific updates, innovative ideas, and pressing issues in their field. Participants can gain valuable insights ultimately improving the care and outcomes of patients with hematologic malignancies. 

Target Audience

This activity has been designed to meet the educational needs of hematologist, oncologist and advanced practice providers that are involved in the care of patients with hematologic malignancies.

Learning Objectives

At the conclusion of this activity, participants should be able to:

Multiple Myeloma
• Evaluate new induction therapies for transplant eligible and ineligible patients
• Assess T- cell redirecting treatment in relapsed MM 

Diffuse B-Cell Lymphoma
• Identify evolving standards of care for aggressive lymphoma including new agents
• Describe the role of immunotherapy in Hodgkin and Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia
• Establish the changing standards of care to initial and subsequent treatment with novel targeted agents
• Assess the role of evolving therapies for malignant B-cell including recent FDA approvals

Acute Leukemia
• Explain the advances in the novel therapeutic strategies in the newly diagnosed and relapsed acute leukemias
• Asses new developments in the field of cellular therapies for acute leukemias

Course summary
Available credit: 
  • 3.00 AMA PRA Category 1 Credit™
    HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    HCA Healthcare Continental Division designates this for a maximum of 3.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 3.00 Attendance
Course opens: 
03/08/2024
Course expires: 
12/31/2026
Course Director(s)

Jeffrey Matous, MD

has a financial relationship (Professional Services) with Janssen Pharmacyclic's;.
has a financial relationship (Professional Services) with BeiGene;.
Co-Director(s)

Vicki Snider, RN, BSN, OCN

has no relevant financial relationships to disclose at this time.
Planner(s)

Jeffrey Matous, MD

has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Janssen Pharmacyclic's;.

Vicki Snider, RN, BSN, OCN

has no relevant financial relationships to disclose at this time.
Speaker(s)

Aref Al-Kali, MD

has a financial relationship (Grant Or Contract) with Aprea;.
has a financial relationship (Grant Or Contract) with H3B Biomedicine/Hemavant;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with ASTEX;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.

Caitlin Costello, MD

has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with BMS;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Regeneron;.

Matt Lunning, D.O. FACP

has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with GenMab;.
has a financial relationship (Professional Services) with Loxo;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with Recordati;.
has a financial relationship (Professional Services) with ViTToria;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Janssen;.

Sameer Parikh

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Ascentage Pharma;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Eli Lilly;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Novalgen Limited;.
has a financial relationship (Professional Services) with Kite pharma;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with MingSight Pharmaceuticals;.
has a financial relationship (Professional Services) with TG Therapeutics;.
Moderator(s)

Jeffrey Matous, MD

has a financial relationship (Professional Services) with Janssen Pharmacyclic's;.
has a financial relationship (Professional Services) with BeiGene;.
Reviewer(s)

Stacy Weiss, PhD, PhD

has no relevant financial relationships to disclose at this time.

Accreditation: The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation: The HCA Healthcare Continental Division designates this enduring activity for a maximum of 3.00 AMA PRA Category 1TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose

Available Credit

  • 3.00 AMA PRA Category 1 Credit™
    HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    HCA Healthcare Continental Division designates this for a maximum of 3.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 3.00 Attendance
Please login or register to take this course.

Activity Registration Requirements

Learners must have a CME.HealthONEcares.com account in order to access/complete the following requirements. To complete the activity, attendees must...

  1. Participate in the activity
  2. Complete Pre/Post Test
  3. Complete the Survey & Activity Evaluation

Learners who complete the requirements above will receive the designated credits they are eligible for. Learners interested in CME credit must verify their profession is listed in their profile in order to be eligible for credits.

Required Hardware/software

For our online courses we recommend the following hardware/software to successfully view and complete the contents of this course:

For ease of use, we strongly recommend using a desktop computer to complete this course. The following desktop web browsers are compatible with our system:

Desktop: Chrome, Internet Explorer, MS Edge, Safari

While not recommended, if you are familiar with completing courses online you may complete this course using a mobile device. For those wishing to complete this activity on Mobile, the following systems are recommended:

Apple iPhones and iPad devices on iOS 10 or later
Android phones and tablets on Android OS 4.4 or later using the supported web browsers listed above.

If you encounter any issues while accessing our courses, please contact CME@HealthONEcares.com